IMDX

Insight Molecular Diagnostics In…

• PUBT·13h ago

  Insight Molecular Diagnostics says Clinical Chemistry study shows 99.2% agreement between GraftAssure and rival NGS dd-cfDNA test at 0.5% threshold

• PUBT·5d ago

  Insight Molecular Diagnostics says study shows GraftAssure CM-Score lifts kidney transplant rejection PPV to 81%

• PUBT·06/09 20:06

  Insight Molecular Diagnostics to showcase GraftAssure at American Transplant Congress

• TipRanks·05/20 05:35

  Insight Molecular Diagnostics Balances Progress and Cash Burn

• TipRanks·05/15 12:01

  Analysts Have Conflicting Sentiments on These Healthcare Companies: Aquestive Therapeutics (AQST), Sangamo Therapeutics (OtherSGMO) and Insight Molecular Diagnostics (IMDX)

• TipRanks·05/15 00:31

  OncoCyte’s Earnings Call Maps Risky Path to Launch

• TipRanks·05/14 13:19

  Lake Street Remains a Buy on Insight Molecular Diagnostics (IMDX)

• TipRanks·05/14 11:45

  Insight Molecular Diagnostics Maintained at Buy as GraftAssure Platform Gains Traction; $9 Price Target Reaffirmed

• Seeking Alpha·05/14 00:31

  Insight Molecular Diagnostics expects about $0.25M Q2 2026 revenue while projecting second-quarter cash burn above $9M

• Reuters·05/13 20:22

  Insight Molecular Diagnostics Q1 loss narrows as costs drop

• Dow Jones·05/13 20:17

  *Insight Molecular Diagn 1Q Loss/Shr 12c >IMDX

• Dow Jones·05/13 20:17

  *Insight Molecular Diagn 1Q Rev $32,000 >IMDX

• PUBT·05/13 20:14

  Insight Molecular Diagnostics Q1 FY26 net loss narrows to $4.29 million; revenue drops to $32,000

• Seeking Alpha·05/13 20:12

  Insight Molecular Diagnostics Inc. GAAP EPS of -$0.12 beats by $0.14, revenue of $0.32M beats by $0.09M

• PUBT·05/13 20:06

  Insight Molecular Diagnostics amends 8-K, reclassifies Quest agreement disclosure to Item 8.01